Associate Professor Dr. Tamboli joined UAMS as an Associate Professor of Medicine in 2011. He directs the Inflammatory Bowel Diseases services offered through the Division of Gastroenterology & Hepatology at UAMS. Dr. Tamboli received his medical degree from the University of Alberta in Edmonton, Canada and also completed a residency in internal medicine and Gastroenterology fellowship (FRCPC) at the University of Alberta. Following this, he spent almost one year as a clinical research fellow at the Hospital Claude Huriez in CHRU de Lille, France and then also spent one year as GI fellow at the University of Iowa Hospitals and pursued a graduate training program in clinical investigation from the University of Iowa. Previous to UAMS, Dr. Tamboli was an Assistant Professor of Medicine at the University of Iowa Carver College of Medicine.
2004: Gastroenterology Fellowship, University of Iowa, Iowa City, USA (PGY 06)
2003: Clinical Research Fellow in Inflammatory Bowel Diseases, Department of Hepato-Gastroenterology & Equipe Mixte INSERM 0114, Service des Maladies de l’Appareil Digestif et de la Nutrition, Hôpital Claude Huriez, CHRU de Lille, France
2002: Gastroenterology Fellowship (FRCPC), University of Alberta, Edmonton, Canada (PGY 04-05)
2000: Internal Medicine residency (FRCPC), University of Alberta, Edmonton, Canada (PGY 01-03)
Fellow, The Royal College of Physicians & Surgeons of Canada
Alberta Medical Association
American Gastroenterology Association
Society for Epidemiological Research
Licensure / Certifications
Gastroenterology, American Board of Internal Medicine
Gastroenterology, The Royal College of Physicians and Surgeons of Canada
Internal Medicine, American Board of Internal Medicine
Internal Medicine, The Royal College of Physicians and Surgeons of Canada
United States Medical Licensing Examination
Licentiate, Medical Council of Canada
Chronic Inflammatory Bowel Diseases
Epidemiology of chronic inflammatory bowel diseases (IBD). More specifically, research efforts are focused upon identifying environmental risk factors for IBD, with consideration of concurrent genetic and microbiological cofactors. Please contact Dr. Tamboli for more information about participating in one of the studies, or for professional collaborations.
Brian Hughes, MD
Tamboli CP, Good MR, Reynolds EM, Sharma P, Mitros FA. Anti-Yersinia Antibodies Are Not Associated With Microscopic Colitis in an American Case-control Study. Scandinavian Journal of Gastroenterology 2011;46(12):1442-8.
Tamboli CP, Doman DB, Patel A. Current and Future Role of Biomarkers in Crohn's Disease Risk Assessment and Treatment. Clinical and Experimental Gastroenterology 2011;4:127-140. DOI: 10.2147/CEG.S18187
Ali, S. Tamboli CP. Advances in Epidemiology and Diagnosis of Inflammatory Bowel Diseases. Current Gastroenterology Reports 2008 Dec;10(6):576-84.
Tamboli CP. How do Genetics Help an Understanding of IBD Epidmiology? In: Fiocchi C, Katz J, Prantera C (eds). Inflammatory Bowel Diseases; 2008; Volume 14: S29-30.
Yan J, Tamboli CP. Testing concordance of clinical characteristics in familial studies with application to inflammatory bowel diseases. Biom J. 2007 Dec;49(6):840-53.
Tamboli CP. Current medical therapy for chronic inflammatory bowel diseases. Surg Clin North Am. 2007 Jun;87(3):697-725.
Malamut G, Cabane C, Dubuquoy L, Malapel M, Derijard B, Gay J, Tamboli C, Colombel JF, Desreumaux P. No Evidence for an Involvement of the P38 and JNK Mitogen-Activated Protein in Inflammatory Bowel Diseases. Digestive Diseases & Sciences 2006;51(8):1443-53.
Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis as a prerequisite for IBD. Gut 2004;53:1057.
Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004; 126:1533-1549.
Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in Inflammatory Bowel Disease. Gut 2004;53:1-4.